Search research articles
Contact Us
Filters
Showing results (131-140 of 252) with videos related to
Page
of 26
Sort By:
European Journal of Haematology
|
August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial
Lutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
British Journal of Haematology
|
December 29, 2018
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial
Boris Böll, Annette Plütschow, Carolin Bürkle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2020
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy
Paul J Bröckelmann, Horst Müller, Teresa Guhl, et al.
Human Gene Therapy
|
August 30, 2017
Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use
Dominik Lock, Nadine Mockel-Tenbrinck, Katharina Drechsel, et al.
The Lancet. Haematology
|
October 7, 2018
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials
Bastian von Tresckow, Stefanie Kreissl, Helen Goergen, et al.
Hemasphere
|
March 24, 2025
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial
Alexander Fosså, Daniel Molin, Paul J Bröckelmann, et al.
The Lancet. Haematology
|
March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)
Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
European Journal of Haematology
|
September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.
Blood
|
January 31, 2014
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
Dennis A Eichenauer, Indra Thielen, Heinz Haverkamp, et al.
Blood
|
February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Boris Böll, Helen Goergen, Karolin Behringer, et al.
Page
of 26
Search research articles
Search
Showing results (131-140 of 252) with videos related to
Sort By:
Page
of 26
European Journal of Haematology
|
August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial
Lutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
British Journal of Haematology
|
December 29, 2018
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial
Boris Böll, Annette Plütschow, Carolin Bürkle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2020
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy
Paul J Bröckelmann, Horst Müller, Teresa Guhl, et al.
Human Gene Therapy
|
August 30, 2017
Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use
Dominik Lock, Nadine Mockel-Tenbrinck, Katharina Drechsel, et al.
The Lancet. Haematology
|
October 7, 2018
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials
Bastian von Tresckow, Stefanie Kreissl, Helen Goergen, et al.
Hemasphere
|
March 24, 2025
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial
Alexander Fosså, Daniel Molin, Paul J Bröckelmann, et al.
The Lancet. Haematology
|
March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)
Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
European Journal of Haematology
|
September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.
Blood
|
January 31, 2014
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
Dennis A Eichenauer, Indra Thielen, Heinz Haverkamp, et al.
Blood
|
February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Boris Böll, Helen Goergen, Karolin Behringer, et al.
Page
of 26